Table 2. LLT at the time of and post ACS.
| n / N , (%) | Prior | Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 |
|---|---|---|---|---|---|---|
| Any LLT | 626/1944 (32.2) | 1837/1944 (94.5) | 1685/1767 (95.4) | 1685/1774 (95.0) | 1587/1669 (95.1) | 1411/1501 (94.0) |
| Statin | 531/1944 (27.3) | 1819/1944 (93.6) | 1665/1767 (94.2) | 1661/1774 (93.6) | 1556/1669 (93.2) | 1385/1501 (92.3) |
| Intensive statin § | 31/1944 (1.6) | 160/1944 (8.2) | 177/1767 (10.0) | 168/1774 (9.5) | 164/1669 (9.8) | 158/1501 (10.5) |
| PCSK9 inhibitors | 0/1944 (0) | 0/1944 (0) | 0/1767 (0) | 2/1772 (0.1) | 5/1670 (0.3) | 6/1495 (0.4) |
| Fibrates | 35/1944 (1.8) | 14/1944 (0.7) | 15/1768 (0.8) | 15/1775 (0.8) | 15/1670 (0.9) | 21/1499 (1.4) |
| Ezetimibe | 40/1944 (2.1) | 75/1944 (3.9) | 94/1767 (5.3) | 121/1775 (6.8) | 154/1668 (9.2) | 174/1499 (11.6) |
| EPA/DHA | 70/1944 (3.6) | 84/1944 (4.3) | 87/1768 (4.9) | 109/1775 (6.1) | 111/1672 (6.6) | 115/1496 (7.7) |
§ Defined as atorvastatin 20 mg, rosuvastatin ≥ 10 mg, or pitavastatin 4 mg
ACS, acute coronary syndrome; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LLT, lipid-lowering therapy; PCSK9, proprotein convertase subtilisin/kexin type 9.